Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT

PHASE II IND APPROVAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF PREVIOUSLY TREATED HR+/HER2 NEGATIVE OR LOW EXPRESSION RELAPSED OR METASTATIC BREAST CANCER

This announcement is made by TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the phase II clinical trial of the Company's core product Tinengotinib (TT-00420) in combination with Fulvestrant for the treatment of previously treated hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative or low expression（HER2-) relapsed or metastatic breast cancer has obtained Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) of the PRC on September 10, 2025.

This is an open-label, multicenter phase II clinical study conducted in China to evaluate the safety, efficacy, and pharmacokinetics of Tinengotinib tablets in combination with Fulvestrant injection for the treatment of patients with previously treated HR+/HER2- relapsed or metastatic breast cancer.

Early clinical study results of Tinengotinib monotherapy demonstrated encouraging clinical efficacy in HR+/HER2- breast cancer patients who have undergone multiple treatments, such as endocrine therapies, CDK4/6 inhibitor therapies, and chemotherapies. Preclinical results demonstrated that Tinengotinib in combination with Fulvestrant exhibited a synergistic pharmacological effect against breast cancer cells resistant to endocrine therapy. Therefore, the clinical treatment strategy of Tinengotinib in combination with Fulvestrant may bring a new treatment option for the treatment of such breast cancer patients.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant products will ultimately be successfully developed and marketed by the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, September 10, 2025

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.